STOCK TITAN
  1. Home
  2. News
  3. ATNM

Actinium Pharmaceuticals Inc - ATNM STOCK NEWS

Welcome to our dedicated news page for Actinium Pharmaceuticals (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Actinium Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Actinium Pharmaceuticals's position in the market.

News
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. presented results from the Phase 3 SIERRA trial of Iomab-B at the European Bone Marrow Transplant Annual Meeting, showing higher remission rates and durable complete remission in patients with active relapsed or refractory acute myeloid leukemia. The study revealed a median overall survival of 5.49 months in TP53 positive patients receiving Iomab-B, compared to 1.66 months in those who did not receive it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. announces positive Phase 3 SIERRA trial results for Iomab-B in patients with TP53 mutation at the European Bone Marrow Transplant Society meeting. The trial showed high statistical significance in achieving durable Complete Remission and 100% BMT access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.32%
Tags
clinical trial
-
News
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. announces a potential breakthrough in targeted radiotherapy conditioning with Iomab-ACT, aiming to replace non-targeted chemotherapy in cell and gene therapies. The collaboration with UT Southwestern for a clinical trial on CAR T-cell therapy shows promising results in reducing toxicities like ICANS and CRS. Iomab-ACT presents a significant market opportunity in the growing field of cellular and gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
clinical trial fda approval
News
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. announces a strategic initiative to manufacture Actinium-225 using a proprietary cyclotron-based method. The company's technology is supported by 5 U.S. patents, 49 international patents, and significant technical expertise. Actinium-225 produced by this method is highly pure, cost-effective, and has higher yields. The initiative includes a multi-million-dollar investment to scale up production to meet growing demand. Actinium aims to collaborate globally to maximize the value of its patents and capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.54%
Tags
none
-
News
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. reports positive Phase 3 SIERRA trial results for Iomab-B in treating r/r AML patients 65+ years at TCT Meetings. Unprecedented 100% BMT access and engraftment with improved long-term survival outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.14%
Tags
clinical trial
-
News
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) highlighted positive results from the Phase 3 SIERRA trial of Iomab-B, showing significant improvements in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B. The trial demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation, leading to complete remissions in over 50% of patients. The company also presented promising data on radiopharmaceutical dosimetry and early results from a Phase 1 study using Iomab-ACT conditioning with CD19 CAR-T therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
News
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) announced that five abstracts have been accepted for presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR. The presentations will highlight Iomab-B and Iomab-ACT CD45 targeted conditioning for bone marrow transplant and CAR-T cellular therapy. Two oral presentations will feature results from the Phase 3 SIERRA trial of Iomab-B, showing improved outcomes for patients with high-risk relapsed/refractory acute myeloid leukemia, including those with a TP53 mutation. The posters will cover topics such as dose-response for durable complete remission and low-dose targeted radioimmunotherapy for patients with relapsed or refractory B-Cell ALL or DLBCL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
none
-
News
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) announced positive Phase 3 SIERRA trial results for Iomab-B, a targeted radiotherapeutic for relapsed or refractory acute myeloid leukemia (AML) patients with TP53 mutation. The trial showed significantly improved survival, durable complete remission, and doubled median overall survival compared to the control arm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
none
-
News
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) highlighted the positive results from the Phase 3 SIERRA trial of Iomab-B and Phase 1 trial of Actimab-A at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH). Iomab-B improved overall survival in patients with TP53 mutation with active, relapsed, or refractory AML, demonstrating a significantly greater median overall survival of 5.49 months compared to 1.66 months in the control arm. Actimab-A in combination with Venetoclax was well-tolerated and achieved complete responses, supporting its continued evaluation in relapsed/refractory AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
none
News
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
Rhea-AI Summary
Actinium Pharmaceuticals, Inc. (ATNM) announces that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual ASH Meeting, highlighting the differentiated capabilities of Iomab-B and Actimab-A in improving overall survival in patients with relapsed or refractory AML with a TP53 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
Stock ATNM logo
Actinium Pharmaceuticals Inc

NYSE:ATNM

ATNM Rankings

#3737 Ranked by Market Cap
#4913 Ranked by Stock Gains
N/A Ranked by Dividends

ATNM Stock Data

227.53M
28.61M
2.16%
24.57%
7.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ATNM

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o